IBDEI2EA ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40632,2)
 ;;=^5009023
 ;;^UTILITY(U,$J,358.3,40633,0)
 ;;=L03.031^^159^1993^111
 ;;^UTILITY(U,$J,358.3,40633,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40633,1,3,0)
 ;;=3^Cellulitis of Right Toe
 ;;^UTILITY(U,$J,358.3,40633,1,4,0)
 ;;=4^L03.031
 ;;^UTILITY(U,$J,358.3,40633,2)
 ;;=^5009025
 ;;^UTILITY(U,$J,358.3,40634,0)
 ;;=L03.032^^159^1993^104
 ;;^UTILITY(U,$J,358.3,40634,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40634,1,3,0)
 ;;=3^Cellulitis of Left Toe
 ;;^UTILITY(U,$J,358.3,40634,1,4,0)
 ;;=4^L03.032
 ;;^UTILITY(U,$J,358.3,40634,2)
 ;;=^5009026
 ;;^UTILITY(U,$J,358.3,40635,0)
 ;;=L03.041^^159^1993^26
 ;;^UTILITY(U,$J,358.3,40635,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40635,1,3,0)
 ;;=3^Acute Lymphangitis of Right Toe
 ;;^UTILITY(U,$J,358.3,40635,1,4,0)
 ;;=4^L03.041
 ;;^UTILITY(U,$J,358.3,40635,2)
 ;;=^5009028
 ;;^UTILITY(U,$J,358.3,40636,0)
 ;;=L03.042^^159^1993^20
 ;;^UTILITY(U,$J,358.3,40636,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40636,1,3,0)
 ;;=3^Acute Lymphangitis of Left Toe
 ;;^UTILITY(U,$J,358.3,40636,1,4,0)
 ;;=4^L03.042
 ;;^UTILITY(U,$J,358.3,40636,2)
 ;;=^5009029
 ;;^UTILITY(U,$J,358.3,40637,0)
 ;;=M34.0^^159^1993^249
 ;;^UTILITY(U,$J,358.3,40637,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40637,1,3,0)
 ;;=3^Progressive Systemic Sclerosis
 ;;^UTILITY(U,$J,358.3,40637,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,40637,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,40638,0)
 ;;=M34.1^^159^1993^91
 ;;^UTILITY(U,$J,358.3,40638,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40638,1,3,0)
 ;;=3^CR(E)ST Syndrome
 ;;^UTILITY(U,$J,358.3,40638,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,40638,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,40639,0)
 ;;=M34.2^^159^1993^273
 ;;^UTILITY(U,$J,358.3,40639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40639,1,3,0)
 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
 ;;^UTILITY(U,$J,358.3,40639,1,4,0)
 ;;=4^M34.2
 ;;^UTILITY(U,$J,358.3,40639,2)
 ;;=^5011780
 ;;^UTILITY(U,$J,358.3,40640,0)
 ;;=M34.81^^159^1993^275
 ;;^UTILITY(U,$J,358.3,40640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40640,1,3,0)
 ;;=3^Systemic Sclerosis w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,40640,1,4,0)
 ;;=4^M34.81
 ;;^UTILITY(U,$J,358.3,40640,2)
 ;;=^5011781
 ;;^UTILITY(U,$J,358.3,40641,0)
 ;;=M34.82^^159^1993^276
 ;;^UTILITY(U,$J,358.3,40641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40641,1,3,0)
 ;;=3^Systemic Sclerosis w/ Myopathy
 ;;^UTILITY(U,$J,358.3,40641,1,4,0)
 ;;=4^M34.82
 ;;^UTILITY(U,$J,358.3,40641,2)
 ;;=^5011782
 ;;^UTILITY(U,$J,358.3,40642,0)
 ;;=M34.83^^159^1993^277
 ;;^UTILITY(U,$J,358.3,40642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40642,1,3,0)
 ;;=3^Systemic Sclerosis w/ Polyneuropathy
 ;;^UTILITY(U,$J,358.3,40642,1,4,0)
 ;;=4^M34.83
 ;;^UTILITY(U,$J,358.3,40642,2)
 ;;=^5011783
 ;;^UTILITY(U,$J,358.3,40643,0)
 ;;=M34.89^^159^1993^274
 ;;^UTILITY(U,$J,358.3,40643,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40643,1,3,0)
 ;;=3^Systemic Sclerosis NEC
 ;;^UTILITY(U,$J,358.3,40643,1,4,0)
 ;;=4^M34.89
 ;;^UTILITY(U,$J,358.3,40643,2)
 ;;=^5011784
 ;;^UTILITY(U,$J,358.3,40644,0)
 ;;=M34.9^^159^1993^278
 ;;^UTILITY(U,$J,358.3,40644,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40644,1,3,0)
 ;;=3^Systemic Sclerosis,Unspec
 ;;^UTILITY(U,$J,358.3,40644,1,4,0)
 ;;=4^M34.9
 ;;^UTILITY(U,$J,358.3,40644,2)
 ;;=^5011785
 ;;^UTILITY(U,$J,358.3,40645,0)
 ;;=R21.^^159^1993^257
 ;;^UTILITY(U,$J,358.3,40645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40645,1,3,0)
 ;;=3^Rash/Nonspecific Skin Eruption
 ;;^UTILITY(U,$J,358.3,40645,1,4,0)
 ;;=4^R21.
